Get started
Author

Pantelis Litsardopoulos

Observed name: P. Litsardopoulos
OpenAlex ID: A5075883974
Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity
2019 · Andreas A. Argyriou, Jordi Bruna, et al. · Supportive Care in Cancer · 30
An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management
2021 · Andreas A. Argyriou, Dimos-Dimitrios Mitsikostas, et al. · Expert Review of Neurotherapeutics · 29
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
2023 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · European Journal of Neurology · 25
PDF
Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study
2024 · Andreas A. Argyriou, Jordi Bruna, et al. · Journal of the Peripheral Nervous System · 22
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
2023 · Michail Vikelis, Emmanouil V. Dermitzakis, et al. · Journal of Clinical Medicine · 17
PDF
Real world, open label experience with lacosamide against acute painful oxaliplatin‐induced peripheral neurotoxicity
2020 · Andreas A. Argyriou, Foteini Kalofonou, et al. · Journal of the Peripheral Nervous System · 17
Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis
2020 · Michail Vikelis, Emmanouil V. Dermitzakis, et al. · Journal of Clinical Medicine · 13
PDF
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
2023 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · Journal of Clinical Medicine · 11
PDF
Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion
2020 · Andreas A. Argyriou, Michail Vikelis, et al. · Expert Review of Neurotherapeutics · 11
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine
2024 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · Toxins · 10
PDF
Gender and age effects on the incidence and severity of chemotherapy-induced neuropathic pain: a propensity score matching analysis
2025 · Andreas A. Argyriou, Roser Velasco, et al. · BMC Cancer · 9
PDF
Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity
2020 · Andreas A. Argyriou, Foteini Kalofonou, et al. · Journal of the Peripheral Nervous System · 8
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine
2024 · Emmanouil V. Dermitzakis, Michail Vikelis, et al. · Journal of Clinical Medicine · 7
PDF
Pneumococcal Otogenic Meningitis Complicated With Pneumocephalus and Coma State
2020 · Despoina Liourdi, Pantelis Litsardopoulos, et al. · Cureus · 7
PDF
Irreversible diffuse hypoxic-ischemic encephalopathy, secondary to type I Kounis syndrome
2019 · Haralabos Anastogiannis, Pantelis Litsardopoulos, et al. · International Journal of Neuroscience · 6
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group
2026 · Emmanouil V. Dermitzakis, Andreas A. Argyriou, et al. · The Journal of Headache and Pain · 4
Effects of Pausing and Re‐Initiating Fremanezumab After Continuous 24‐Month Treatment for Preventing Difficult‐To‐Treat Migraine: Prospective, Multicenter, Real‐World Data From the GRASP Study Group
2025 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · European Journal of Neurology · 4
PDF
OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group
2025 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · Toxins · 3
PDF
Real world, open label prospective experience of supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) for episodic migraine prophylaxis
2020 · Michail Vikelis, Emmanouil V. Dermitzakis, et al. · 3
PDF
Fatal, paraparetic acute motor axonal neuropathy, early complicating chemotherapy with nab-paclitaxel
2018 · Pantelis Litsardopoulos, Christos Bikas, et al. · Anti-Cancer Drugs · 3
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry
2024 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · Expert Review of Neurotherapeutics · 2
Systemic lupus erythematosus manifested as drug-resistant mesial temporal lobe epilepsy
2016 · P. Polychronopoulos, G. Giannopoulos, et al. · Neurological Sciences · 2
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study group
2026 · Andreas A. Argyriou, Emmanouil V. Dermitzakis, et al. · Cephalalgia · 1
Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group
2026 · Emmanouil V. Dermitzakis, Andreas A. Argyriou, et al. · Cephalalgia
Works count: 24
Citation count: 244
H-index: 10
I10-index: 10
Year
Topic
Type